Skip to main content
Log in

Commentary on: “The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma.” By Burzynski et al.

  • Commentary
  • Published:
Child's Nervous System Aims and scope Submit manuscript

The Original Article was published on 10 April 2014

Abstract

A potential effective therapy for diffuse intrinsic pontine glioma (DIPG) is far to be developed. There are no “shortcuts” to reach this goal. Only a rigid, scientific, and ethically correct approach can help develop effective therapeutic approaches for such a devastating brain tumor. There are no alternative ways. The children affected by DIPG deserve to become the focus of serious collaborative researches. For these children, there are many “lacks” which should be promptly corrected such as the lack of knowledge, the lack of basic and clinical scientists’ passion to the problem of finding “the solution” for DIPG, the lack of rigid methods to run research in this frustrating field, the lack of research proposals, and the lack of serious, despite not magic, protocols to offer them.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Rowe JM (2013) Important milestones in acute leukemia in 2013. Best Pract Res Clin Haematol 26(3):241–4

    Article  PubMed  Google Scholar 

  2. Truant TL, Porcino AJ, Ross BC, Wong ME, Hilario CT (2013) Complementary and alternative medicine (CAM) use in advanced cancer: a systematic review. J Support Oncol 11(3):105–13

    Article  PubMed  Google Scholar 

  3. Jansen MH, van Vuurden DG, Vandertop WP, Kaspers GJ (2012) Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. Cancer Treat Rev 38(1):27–35

    Article  CAS  PubMed  Google Scholar 

  4. Khatua S, Moore KR, Vats TS, Kestle JR (2011) Diffuse intrinsic pontine glioma-current status and future strategies. Childs Nerv Syst 27(9):1391–7

    Article  PubMed  Google Scholar 

  5. Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau L, Dzamba M, Morrison A, Lewis P, Bouffet E, Bartels U, Zuccaro J, Agnihotri S, Ryall S, Barszczyk M, Chornenkyy Y, Bourgey M, Bourque G, Montpetit A, Cordero F, Castelo-Branco P, Mangerel J, Tabori U, Ho KC, Huang A, Taylor KR, Mackay A, Bendel AE, Nazarian J, Fangusaro JR, Karajannis MA, Zagzag D, Foreman NK, Donson A, Hegert JV, Smith A, Chan J, Lafay-Cousin L, Dunn S, Hukin J, Dunham C, Scheinemann K, Michaud J, Zelcer S, Ramsay D, Cain J, Brennan C, Souweidane MM, Jones C, Allis CD, Brudno M, Becher O, Hawkins (2014) Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 46(5):451–456

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Wu G, Broniscer A, McEachron TA, Lu C et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. St. Jude Children’s Research Hospital—Washington University Pediatric Cancer Genome Project. Nat Genet 44(3):251–3

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E, Bartels U, Albrecht S, Schwartzentruber J, Letourneau L, Bourgey M, Bourque G, Montpetit A, Bourret G, Lepage P, Fleming A, Lichter P, Kool M, von Deimling A, Sturm D, Korshunov A, Faury D, Jones DT, Majewski J, Pfister SM, Jabado N, Hawkins C (2012) K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124(3):439–47

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Kristensen VN, Lingjærde OC, Russnes HG, Vollan HK, Frigessi A, Børresen-Dale AL (2014) Principles and methods of integrative genomic analyses in cancer. Nat Rev Cancer 14(5):299–313

    Article  CAS  PubMed  Google Scholar 

  9. Zwaan CM, Kearns P, Caron H, Verschuur A, Riccardi R, Boos J, Doz F, Geoerger B, Morland B, Vassal G (2010) The role of “innovative therapies for children with cancer” (ITCC) European Consortium. Cancer Treat Rev 36:328–334

    Article  PubMed  Google Scholar 

  10. Children Brain Tumour Research Consortium. http://cbttc.org/investigators.php (accessed July 2014)

  11. Wilmott G (2013) Regulating clinical trials in Europe. Lancet Oncol 14:453–454

    Article  Google Scholar 

  12. Vassal G, Fitzgerald E, Schrappe M et al (2014) Challenges for children and adolescents with cancer in Europe. Pediatr Blood Cancer 7:1–7

    Google Scholar 

  13. Pritchard-Jones K (2008) SIOP Europe Clinical trials for children with cancer in Europe—still a long way from harmonisation: a report from SIOP Europe. Eur J Cancer 44(15):2106–11

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Giorgio Perilongo.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Perilongo, G. Commentary on: “The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma.” By Burzynski et al.. Childs Nerv Syst 30, 2071–2072 (2014). https://doi.org/10.1007/s00381-014-2557-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00381-014-2557-6

Keywords

Navigation